Item 5.07 Submission of Matters to a Vote of Security Holders

On May 12, 2022, Neoleukin Therapeutics, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were adopted:

1.Election of two Class II Directors, Jonathan G. Drachman, M.D. and Sarah B. Noonberg, M.D., Ph.D., each to serve a three-year term, which will expire at the 2025 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal. The vote tally was as follows:



              Nominees                  Shares For       Shares Withheld       Broker Non-Votes
  Jonathan G. Drachman, M.D.            24,103,788           108,548              6,226,831
  Sarah B. Noonberg, M.D., Ph.D.        23,994,699           217,637              6,226,831

2.Ratification of appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. The vote tally was as follows:



                   Shares For       Shares Against       Shares Abstaining
                   30,382,561           42,629                 13,977

3.Approval, by non-binding advisory vote, of the compensation paid by the Company to its named officers. The vote tally was as follows:



          Shares For       Shares Against       Shares Abstaining        Broker Non-Votes
          22,484,586          1,701,779               25,971                6,226,831

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses